Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat
暂无分享,去创建一个
[1] Satoru Mitsuboshi. Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database , 2020, British journal of clinical pharmacology.
[2] M. Kolber,et al. Treat‐to‐Target in Gout Management? Comment on the Article by FitzGerald et al , 2020, Arthritis & rheumatology.
[3] M. Niemi,et al. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin , 2020, Clinical and translational science.
[4] G. Guyatt,et al. 2020 American College of Rheumatology Guideline for the Management of Gout , 2020, Arthritis care & research.
[5] M. Okuda,et al. Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein , 2019, Scientific Reports.
[6] L. Hsu,et al. Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population‐Based Cohort Study and Meta‐Analysis , 2019, Clinical pharmacology and therapeutics.
[7] M. Melbye,et al. Concomitant use of low‐dose methotrexate and NSAIDs and the risk of serious adverse events among patients with rheumatoid arthritis , 2018, Pharmacoepidemiology and drug safety.
[8] D. Hira,et al. BCRP/ABCG2 and high‐alert medications: Biochemical, pharmacokinetic, pharmacogenetic, and clinical implications , 2018, Biochemical pharmacology.
[9] T. Buclin,et al. Renal Drug Transporters and Drug Interactions , 2017, Clinical Pharmacokinetics.
[10] Hirotaka Matsuo,et al. Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations , 2016, Front. Pharmacol..
[11] C. Pui,et al. Preventing and Managing Toxicities of High-Dose Methotrexate , 2016, The oncologist.
[12] K. Migita,et al. Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases , 2016, PloS one.
[13] M. Federico,et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Goodman,et al. Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. , 2015, Clinical and experimental rheumatology.
[15] M. Joerger,et al. Cancer chemotherapy: targeting folic acid synthesis , 2010, Cancer management and research.
[16] B. Haraoui,et al. Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic Review , 2010, The Journal of Rheumatology.
[17] M. Taniwaki,et al. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis , 2010, Annals of Hematology.
[18] K. Schmiegelow. Advances in individual prediction of methotrexate toxicity: a review , 2009, British journal of haematology.
[19] A. Ilchyshyn,et al. Methotrexate Toxicity Induced by Acute Renal Failure , 2005, Journal of the Royal Society of Medicine.
[20] R. Fleischmann. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis , 2003, Expert opinion on drug safety.
[21] B. Bannwarth,et al. Clinical Pharmacokinetics of Low-Dose Pulse Methotrexate in Rheumatoid Arthritis , 1996, Clinical pharmacokinetics.
[22] Y. Maugars,et al. Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths) , 1995, Revue du rhumatisme.
[23] D. Wilkinson. ALLOPURINOL AND AGRANULOCYTOSIS , 1977, The Lancet.